| Summary: | 碩士 === 臺北醫學大學 === 藥學系 === 93 === Abstract
The treatment and repair of the spinal cord injury have been crucial subjects in recent years. In the past, MP was used to be treated with the acute spinal cord injury (SCI), though with great side effects.Recently research shows that after the spinal cord injury are very great relations of the demyelination with the death of oligodendrocyte cell and the damage of axon.
To obviate the multiple genetic mechanisms of MP, the anti-apoptotic protein Bcl-xL gene could be one approvals of developing novel gene delivery systems to avoid the advance side of effect of MP.
We have a nano-size of PM with Bcl-xL gene (pMBP-Bcl-xL-EGFP), driven by oligodendrcytes-specific promoters of Myelin basic protein(MBP) into the spinal cord. Our finding indicate those two days after six doses of oral delivery of 40 μg with 3 times a day, gene expression was observed at 48 h in the spinal cord by immunohistological observation, Bcl-xL western-blotting, m RNA of Bcl-xL by real time PCR, Furthermore, using PM incorporated with MP, we did observe the mRNA of Bcl-xL have sustained in the spinal cord.
|
|---|
